Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer

In the era of precision medicine, genomic profiling of tumors has become a cornerstone of advanced cancer care.

The guideline highlights the importance of genomic profiling in prostate cancer, emphasizing its role in informing treatment decisions and prognosis.

The 2023 CUA guideline, titled “2023 Canadian Urological Association guideline: Genetic testing in prostate cancer”, highlights the importance of genomic profiling in prostate cancer, emphasizing its role in informing treatment decisions and prognosis. According to the document, which cites 90 reference documents, by analyzing tumor-specific alterations, genomic profiling allows clinicians to tailor therapies to the unique molecular characteristics of a patient’s disease.

This quiz, our second in a series of 3 on the guideline, will focus on the CUA’s guidance on the use of genomic profiling in prostate cancer, including indications, recommended methodologies, and interpretation of findings. Join us to evaluate your grasp of this pivotal tool in modern oncology!

Editor’s note: This quiz was composed with the aid of artificial intelligence tools

REFERENCE

1. Rendon RA, Selvarajah S, Wyatt AW, et al. 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer. Can Urol Assoc J. 2023;17(10):314–325. doi:10.5489/cuaj.8588